Windtree Therapeutics, Inc. Accounts Receivable Change

Accounts Receivable Change of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Accounts Receivable Change growth rates and interactive chart.


Highlights and Quick Summary

  • Accounts Receivable Change for the quarter ending June 29, 2019 was $-1.19 Million (a -1362.77% decrease compared to previous quarter)
  • Year-over-year quarterly Accounts Receivable Change decreased by -6347.37%
  • Annual Accounts Receivable Change for 2014 was $67 Thousand (a -200.0% decrease from previous year)
  • Twelve month Accounts Receivable Change ending June 29, 2019 was $-1.05 Million (a -1219.15% decrease compared to previous quarter)
  • Twelve month trailing Accounts Receivable Change increased by 4681.82% year-over-year
Trailing Accounts Receivable Change for the last four month:
29 Jun '19 29 Jun '18 30 Dec '14 29 Sep '14
$-1.05 Million $94 Thousand $67 Thousand $-22 Thousand
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Accounts Receivable Change of Windtree Therapeutics, Inc.

Most recent Accounts Receivable Changeof WINT including historical data for past 10 years.

Interactive Chart of Accounts Receivable Change of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Accounts Receivable Change for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $-1.19
2018 $0.09
2014 $0.02 $0.02 $-0.04 $0.07 $0.07
2013 $-0.07 $-0.07

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.